Crizotinib or vebreltinib response and resistance in advanced non-small cell lung cancer with MET exon 14 skipping
Jiao Yang, Cheng-Di Weng, Han-Min Wang, Jun-Wei Su, Quan-Quan Tan, Xiao-Cheng Lin, Mei-Mei Fang, Zi-Ji Mao, Hua-Jun Chen, Hui Li, Gengpeng Lin, Yi-Long Wu, Yubiao Guo, Jin-Ji Yang · 2026
Read Crizotinib or vebreltinib response and resistance in advanced non-small cell lung cancer with MET exon 14 skipping by Jiao Yang, Cheng-Di Weng, Han-Min Wang, Jun-Wei Su, Quan-Quan Tan, Xiao-Cheng Lin, Mei-Mei Fang, Zi-Ji Mao, Hua-Jun Chen, Hui Li, Gengpeng Lin, Yi-Long Wu, Yubiao Guo, Jin-Ji Yang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13396101.txt.
Description
Jiao Yang and others weigh crizotinib against vebreltinib in lung cancers with MET exon 14 skips in a 2026 real-world study. These gene faults hit 1 to 3 percent of non-small lung cancers, and drug spurn stays a snag.
Among 24 patients, middle time without growth hit 7.0 months in all, with crizotinib at 6.1 months and half worsening in three months, while vebreltinib held longer. Tumor defense maps and lab-grown tumor balls in dishes from three patients added response hints. Cancer doctors gain head-to-head data for picking between MET drugs with more sureness.
Catalog record
| CREATOR | Jiao Yang, Cheng-Di Weng, Han-Min Wang, Jun-Wei Su, Quan-Quan Tan, Xiao-Cheng Lin, Mei-Mei Fang, Zi-Ji Mao, Hua-Jun Chen, Hui Li, Gengpeng Lin, Yi-Long Wu, Yubiao Guo, Jin-Ji Yang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |